A comprehensive review on the research progress of PTP1B inhibitors as antidiabetics.

Abstract

Diabetes mellitus (DM) is a serious global health concern affecting over 500 million people. To put it simply, it is one of the most dangerous metabolic illnesses. Insulin resistance is the root cause of 90% of all instances of diabetes, all of which are classified as Type 2 DM. Untreated, it poses a hazard to civilization since it can lead to terrifying consequences and even death. Oral hypoglycemic medicines presently available act in a variety of ways, targeting various organs and pathways. The use of protein tyrosine phosphatase 1B (PTP1B) inhibitors, on the contrary, is a novel and effective method of controlling type 2 diabetes. PTP1B is a negative insulin signaling pathway regulator; hence, inhibiting PTP1B increases insulin sensitivity, glucose absorption, and energy expenditure. PTP1B inhibitors also restore leptin signaling and are considered a potential obesity target. In this review, we have compiled a summary of the most recent advances in synthetic PTP1B inhibitors from 2015 to 2022 which have scope to be developed as clinical antidiabetic drugs.

• Authors: Neetu Agrawal, Parth Dhakrey, Shilpi Pathak
• Journal: Chemical biology & drug design (Chem Biol Drug Des) Vol. 102 Issue 4 Pg. 921-938 (10 2023) ISSN: 1747-0285 [Electronic] England
• PMID: 37232059 (Publication Type: Journal Article, Review)
• Copyright: © 2023 John Wiley & Sons Ltd.

Chemical References

• Hypoglycemic Agents
• Insulin
• Enzyme Inhibitors
• Protein Tyrosine Phosphatase, Non-Receptor Type 1

Topics

• Humans
• Hypoglycemic Agents (pharmacology, therapeutic use)
• Diabetes Mellitus, Type 2 (drug therapy, metabolism)
• Insulin
• Insulin Resistance
• Obesity (drug therapy)
• Enzyme Inhibitors (pharmacology, therapeutic use)
• Protein Tyrosine Phosphatase, Non-Receptor Type 1 (metabolism)